Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aratana Therapeutics Inc (NASDAQ:PETX)

5.97
Delayed Data
As of 3:59pm ET
 -0.18 / -2.93%
Today’s Change
2.56
Today|||52-Week Range
19.99
+6.99%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Generic
MARKET CAP
$217.4M

Company Description

Aratana Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the licensing, development and commercialization of innovative prescription medications for pets, or pet therapeutics. It delivers innovative prescription medicines that address significant medical needs for cats and dogs (companion animals). The company licenses proprietary, patent-protected compounds from human pharmaceutical and biotechnology companies. Aratana Therapeutics was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.

Contact Information

Aratana Therapeutics, Inc.
11400 Tomahawk Creek Parkway
Leawood Kansas 66103
P:(913) 353-1000
Investor Relations:
(913) 353-1023

Employees

Shareholders

Mutual fund holders48.95%
Other institutional38.80%
Individual stakeholders26.69%

Top Executives

Steven St. PeterPresident, Chief Executive Officer & Director
Craig A. ToomanCFO, Treasurer & Head-Investor Relations
Linda RhodesChief Scientific Officer
Ernst HeinenChief Development Officer
Julia A. StephanusChief Commercial Officer